KRAS G12R
|
Colon Cancer
|
KRAS G12R
|
Colon Cancer
|
cetuximab Resistant: B - Late Trials
|
cetuximab Resistant: B - Late Trials
|
KRAS G12R
|
CRC
|
KRAS G12R
|
CRC
|
panitumumab Resistant: B - Late Trials
|
panitumumab Resistant: B - Late Trials
|
KRAS G12R
|
Pancreatic Adenocarcinoma
|
KRAS G12R
|
Pancreatic Adenocarcinoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
KRAS G12R
|
Pancreatic Cancer
|
KRAS G12R
|
Pancreatic Cancer
|
cobimetinib Sensitive: C3 – Early Trials
|
cobimetinib Sensitive: C3 – Early Trials
|
KRAS G12R
|
HCC
|
KRAS G12R
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12R
|
NSCLC
|
KRAS G12R
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
KRAS G12R
|
Gastric Cancer
|
KRAS G12R
|
Gastric Cancer
|
imatinib Resistant: C4 – Case Studies
|
imatinib Resistant: C4 – Case Studies
|
KRAS G12R
|
CRC
|
KRAS G12R
|
CRC
|
sunitinib Resistant: D – Preclinical
|
sunitinib Resistant: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
trametinib + dasatinib Sensitive: D – Preclinical
|
trametinib + dasatinib Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
dasatinib + SCH772984 Sensitive: D – Preclinical
|
dasatinib + SCH772984 Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Medullary Carcinoma
|
KRAS G12R
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
dasatinib + selumetinib Sensitive: D – Preclinical
|
dasatinib + selumetinib Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
KRAS G12R
|
Thyroid Gland Carcinoma
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Anaplastic Carcinoma
|
KRAS G12R
|
Thyroid Gland Anaplastic Carcinoma
|
GSKJ4 Sensitive: D – Preclinical
|
GSKJ4 Sensitive: D – Preclinical
|